Assertio Holdings Inc (ASRT)
0.9555
-0.02
(-2.51%)
USD |
NASDAQ |
Mar 28, 16:00
0.9555
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 90.77M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -83.66% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.4678 |
Price to Book Value | 0.6578 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.2768 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.06% |
Profile
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |
URL | https://www.assertiotx.com |
Investor Relations URL | https://investor.assertiotx.com/overview/default.aspx |
HQ State/Province | Illinois |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 09, 2024 (est.) |
Last Earnings Release | Mar. 11, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |
URL | https://www.assertiotx.com |
Investor Relations URL | https://investor.assertiotx.com/overview/default.aspx |
HQ State/Province | Illinois |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 09, 2024 (est.) |
Last Earnings Release | Mar. 11, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |